<DOC>
	<DOCNO>NCT02261922</DOCNO>
	<brief_summary>To evaluate effect ticagrelor endothelial function measure flow mediate dilation brachial artery . This compare prasugrel .</brief_summary>
	<brief_title>Ticagrelor Endothelial Function</brief_title>
	<detailed_description>Objective : Demonstrate improvement endothelial function ticagrelor Introduction hypothesis : Ticagrelor prasugrel 2 new platelet antagonist . Both superior clopidogrel use acute coronary syndrome . However , ticagrelor reduce cardiovascular mortality almost 20 % . Prasugrel reduce composite clinical end point cardiovascular mortality , myocardial infarction stroke , decrease mortality . The exact mechanism mortality reduction ticagrelor unclear . Some side effect ticagrelor , brady-arrhythmias dyspnea may relate adenosine release . It thus possible , drug may liberate significant amount adenosine . Prior study demonstrate adenosine beneficial effect endothelial function improve outcome patient acute coronary syndrome . It thus possible ticagrelor may improve endothelial function adenosine like effect . This effect independent platelet inhibition . Prasugrel platelet inhibition effect compare ticagrelor , hypothesis adenosine like effect thus improve endothelial function . Study design : This prospective , randomize , double blind , cross-over study compare 2 new platelet inhibitor potency : ticagrelor prasugrel . Patients stable coronary artery disease randomize one 2 drug . Patients receive one 2 drug period 8 +/- 2 day , stop drug period 14 +/- 2 day , cross receive drug period 8 +/- 2 day . All patient follow measurement : - Flow mediate Dilation ( FMD ) brachial artery - Platelet aggregation response ADP All measurements do : - Baseline 1 ( prior start drug 1 ) - At 8 +/- 2 day ( peak effect drug 1 ) - Baseline 2 ( 14+/- 2 day ; washout prior start drug 2 ) - At 8 +/- 2 day baseline 2 ( peak effect drug 2 ) Measure FMD brachial artery : It perform accord Academic Medical Center Amsterdam pre-established protocol . Measure platelet aggregation : It perform multiplate aggregometer Study End-Points : - Primary : change FMD 2 drug - Secondary : Change platelet aggregation 2 drug - Possible another secondary end-point : Change NO activity blood 2 drug</detailed_description>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Prior MI &gt; 1 year old Prior PCI &gt; 1 year old Prior CABG &gt; 3 month old Known lesion cause 50 % stenosis coronary angiography Acute coronary syndrome within last 6 month Any history bleeding Age &gt; 75 year Weight &lt; 65 kg Prior stroke TIA Platelet count &lt; 100,000 Hemoglobin &lt; 11 mg/dL Patients receive ticagrelor , prasugrel clopidogrel 3 month precede randomization Patients take antithrombotic therapy</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>